FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009287831> ?p ?o ?g. }

• W2009287831 endingPage "9" @default.
• W2009287831 startingPage "1" @default.
• W2009287831 abstract "Expression of epidermal growth factor receptor (EGFR), a potent regulator of cellular homeostasis, is associated with aggressive tumor behavior. The mechanism by which EGFR inhibition functions is unclear, with controversial results demonstrating an effect on the tumor cells, endothelial cells, or pericytes. EGFR activation has been linked to the expression of vascular endothelial growth factor (VEGF), a known mitogen of angiogenesis, but the relationship between these factors and their effect on tumor vessel development is vague. We hypothesized that using an EGFR inhibitor on a human Ewing's sarcoma model would inhibit tumor growth by suppressing vessel proliferation.A cell proliferation assay was performed on the Ewing's sarcoma (SK-NEP-1) cell line. Tumor cells were implanted intrarenally in athymic mice. Animals received daily gavage with vehicle or gefitinib 1 wk following implantation. Mice (n = 12/cohort) were euthanized 6 wk following implantation. Remaining mice were maintained without treatment for 2 wk. Vascular changes were assessed by angiography and immunohistochemically. EGFR and vascular endothelial growth factor (VEGF) expression were quantified using quantitative polymerase chain reaction (qPCR).Gefitinib suppressed in vitro cell growth with an IC(50) = 1.36 μM. Minimal tumor growth suppression was noted at 6 wk (6.01 ± 1.2 g in control versus 4.61 ± 0.9 g treated, P = 0.36). After cessation of gefitinib, tumor growth was increased in both groups (7.37 ± 1.62 g versus 6.77 ± 1.53 g, P = 0.79). Microvessel density was unchanged despite EGFR inhibition (161,000 ± 16,000 pixels versus 135,000 ± 18,000 pixels, P = 0.31). At 6 wk, the vascular maturity index was similar in both groups (3.63 ± 1.12 versus 4.09 ± 1.71, P = 0.83). A downward trend in EGFR expression (49% of control) and an upward trend in VEGF levels (50% of control) occurred in the treated group.EGFR expression was suppressed in cultured cells and xenograft tumors. Despite a cytotoxic effect on cell lines, gefitinib had little effect on tumor growth. No effects on the tumor vasculature were noted in the setting of EGFR suppression, suggesting that angiogenesis induced by SK-NEP-1 cells is refractory to EGFR inhibition. Interestingly, the resulting increase in VEGF expression following EGFR blockade, provides an alternative pro-angiogenic pathway promoting tumor survival." @default.
• W2009287831 created "2016-06-24" @default.
• W2009287831 creator A5016121478 @default.
• W2009287831 creator A5017250643 @default.
• W2009287831 creator A5045062684 @default.
• W2009287831 creator A5047612044 @default.
• W2009287831 creator A5075712958 @default.
• W2009287831 creator A5079435762 @default.
• W2009287831 creator A5089559539 @default.
• W2009287831 date "2012-03-01" @default.
• W2009287831 modified "2023-09-26" @default.
• W2009287831 title "EGFR Inhibition Fails to Suppress Vascular Proliferation and Tumor Growth in a Ewing's Sarcoma Model" @default.
• W2009287831 cites W1963651489 @default.
• W2009287831 cites W1979926405 @default.
• W2009287831 cites W2010078128 @default.
• W2009287831 cites W2010174111 @default.
• W2009287831 cites W2015556441 @default.
• W2009287831 cites W2015812392 @default.
• W2009287831 cites W2023693731 @default.
• W2009287831 cites W2037036887 @default.
• W2009287831 cites W2042103473 @default.
• W2009287831 cites W2043911313 @default.
• W2009287831 cites W2070264012 @default.
• W2009287831 cites W2088971478 @default.
• W2009287831 cites W2089316300 @default.
• W2009287831 cites W2095126639 @default.
• W2009287831 cites W2095483608 @default.
• W2009287831 cites W2106663496 @default.
• W2009287831 cites W2107922742 @default.
• W2009287831 cites W2109294408 @default.
• W2009287831 cites W2117776838 @default.
• W2009287831 cites W2126812050 @default.
• W2009287831 cites W2139691613 @default.
• W2009287831 cites W2142878985 @default.
• W2009287831 cites W2154458783 @default.
• W2009287831 cites W2170793287 @default.
• W2009287831 cites W2413513425 @default.
• W2009287831 doi "https://doi.org/10.1016/j.jss.2011.04.041" @default.
• W2009287831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21658718" @default.
• W2009287831 hasPublicationYear "2012" @default.
• W2009287831 type Work @default.
• W2009287831 sameAs 2009287831 @default.
• W2009287831 citedByCount "11" @default.
• W2009287831 countsByYear W20092878312013 @default.
• W2009287831 countsByYear W20092878312014 @default.
• W2009287831 countsByYear W20092878312015 @default.
• W2009287831 countsByYear W20092878312016 @default.
• W2009287831 countsByYear W20092878312018 @default.
• W2009287831 countsByYear W20092878312019 @default.
• W2009287831 countsByYear W20092878312021 @default.
• W2009287831 crossrefType "journal-article" @default.
• W2009287831 hasAuthorship W2009287831A5016121478 @default.
• W2009287831 hasAuthorship W2009287831A5017250643 @default.
• W2009287831 hasAuthorship W2009287831A5045062684 @default.
• W2009287831 hasAuthorship W2009287831A5047612044 @default.
• W2009287831 hasAuthorship W2009287831A5075712958 @default.
• W2009287831 hasAuthorship W2009287831A5079435762 @default.
• W2009287831 hasAuthorship W2009287831A5089559539 @default.
• W2009287831 hasConcept C126322002 @default.
• W2009287831 hasConcept C134018914 @default.
• W2009287831 hasConcept C142724271 @default.
• W2009287831 hasConcept C167734588 @default.
• W2009287831 hasConcept C170493617 @default.
• W2009287831 hasConcept C2777025900 @default.
• W2009287831 hasConcept C2777506169 @default.
• W2009287831 hasConcept C2778256501 @default.
• W2009287831 hasConcept C2779438470 @default.
• W2009287831 hasConcept C2780394083 @default.
• W2009287831 hasConcept C2780580887 @default.
• W2009287831 hasConcept C502942594 @default.
• W2009287831 hasConcept C54355233 @default.
• W2009287831 hasConcept C62112901 @default.
• W2009287831 hasConcept C71924100 @default.
• W2009287831 hasConcept C86803240 @default.
• W2009287831 hasConceptScore W2009287831C126322002 @default.
• W2009287831 hasConceptScore W2009287831C134018914 @default.
• W2009287831 hasConceptScore W2009287831C142724271 @default.
• W2009287831 hasConceptScore W2009287831C167734588 @default.
• W2009287831 hasConceptScore W2009287831C170493617 @default.
• W2009287831 hasConceptScore W2009287831C2777025900 @default.
• W2009287831 hasConceptScore W2009287831C2777506169 @default.
• W2009287831 hasConceptScore W2009287831C2778256501 @default.
• W2009287831 hasConceptScore W2009287831C2779438470 @default.
• W2009287831 hasConceptScore W2009287831C2780394083 @default.
• W2009287831 hasConceptScore W2009287831C2780580887 @default.
• W2009287831 hasConceptScore W2009287831C502942594 @default.
• W2009287831 hasConceptScore W2009287831C54355233 @default.
• W2009287831 hasConceptScore W2009287831C62112901 @default.
• W2009287831 hasConceptScore W2009287831C71924100 @default.
• W2009287831 hasConceptScore W2009287831C86803240 @default.
• W2009287831 hasIssue "1" @default.
• W2009287831 hasLocation W20092878311 @default.
• W2009287831 hasLocation W20092878312 @default.
• W2009287831 hasOpenAccess W2009287831 @default.
• W2009287831 hasPrimaryLocation W20092878311 @default.
• W2009287831 hasRelatedWork W1965524254 @default.
• W2009287831 hasRelatedWork W2007766970 @default.
• W2009287831 hasRelatedWork W2079688459 @default.

• next